Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma

Xavier Leleu • 10 Jun 2022

EHA 2022

Multiple Myeloma Antibodies Daratumumab Dexamethasone Ixazomib

IFM 2018-02

Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, comments on the toxicity of dexamethasone and discusses the results of IFM 2018-02 (NCT03757221), a Phase II study assessing the safety and efficacy of ixazomib plus daratumumab without dexamethasone in elderly and frail patients with relapsed/refractory (R/R) multiple myeloma. Overall, the study suggested that this combination has a favorable efficacy profile and improved safety in comparison to dexamethasone-based regimens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Janssen, Takeda, BMS, GSK

IMAGE subgroup analysis: real-world experience of Isa-Pd in patients with R/R multiple myeloma

Xavier Leleu • 29 Sep 2023

MagnetisMM-3: correcting hypogammaglobulinemia & using Ig replacement therapy to reduce infections

Xavier Leleu • 29 Sep 2023

Individualizing treatment in transplant-eligible & transplant-ineligible NDMM

Xavier Leleu • 29 Sep 2023

Ongoing studies of elranatamab in frail patients & with DaraPomDex: MagnetisMM-3 & MagnetisMM-5

Xavier Leleu • 9 Jun 2023

Related Videos

Looking forward to COMy 2024: celebrating 10 years

Mohamad Mohty • 17 Apr 2024

Overcoming barriers to treating older patients with myeloma

Sergio Giralt • 16 Apr 2024

The potentially curative role of CAR-T therapy in myeloma

Sergio Giralt • 16 Apr 2024

Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines

Monika Engelhardt • 16 Apr 2024